Mobile Menu Mobile Close

Search

LEARN MORE AT UKONIQ.COM LEARN MORE AT UKONIQ.COM

LEARN MORE ABOUT OUR FEARLESS PURSUIT

LATEST NEWS

TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual...

Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab was generally well tolerated, with no unexpected safety signals BLA submission targeted in Q3 2021 Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET NEW

Read More >

GET INVESTOR
INFORMATION

HEAR OUR
STORY

READ OUR
PUBLICATIONS

EXPLORE OUR
PIPELINE

JOIN OUR
TEAM

HEAR OUR
STORY

EXPLORE OUR
PIPELINE

READ OUR
PUBLICATIONS

JOIN OUR
TEAM

GET INVESTOR
INFORMATION

LATEST NEWS

TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual...

Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab was generally well tolerated, with no unexpected safety signals BLA submission targeted in Q3 2021 Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET NEW

Read More >
logo

Email Us 1-877-575-TGTX (8489)

©2021 TG Therapeutics, Inc. All rights reserved.

You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

CONTINUE Return to tgtherapeutics.com